Background And Objective: To examine a new high-resolution kinetic mapping method for scotoma in age-related macular degeneration.
Patients And Methods: A computer-based program for kinetic visual field mapping was tested in 10 healthy subjects and 14 patients with age-related macular degeneration and fixed preferred retinal locus. The stimulus was presented using a back projector on a screen located 40 cm from the subject. The findings were then compared with static results.
Results: Control group mapping revealed good congruency with the anatomic blind spot. Mapping of the 14 patients with age-related macular degeneration was rapid and revealed good accuracy. The average deviation of the mapping border from the anatomic scotoma border was no more than 3.1% of the scotoma radius. Static mapping of 7 of the patients with age-related macular degeneration was longer and revealed lower accuracy.
Conclusions: The proposed method is more rapid, accurate, and consistent than static mapping. It allows accurate mapping of central scotoma with suprathreshold stimulus, and may be used in the future for detecting the early stages of age-related macular degeneration using subthreshold stimulus.
Download full-text PDF |
Source |
---|
J R Stat Soc Ser C Appl Stat
January 2025
Department of Biostatistics and Health Data Science, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
The aim of dynamic prediction is to provide individualized risk predictions over time, which are updated as new data become available. In pursuit of constructing a dynamic prediction model for a progressive eye disorder, age-related macular degeneration (AMD), we propose a time-dependent Cox survival neural network (tdCoxSNN) to predict its progression using longitudinal fundus images. tdCoxSNN builds upon the time-dependent Cox model by utilizing a neural network to capture the nonlinear effect of time-dependent covariates on the survival outcome.
View Article and Find Full Text PDFClin Ophthalmol
January 2025
Department of Ophthalmology, New Vision Eye Center, Vero Beach, FL, USA.
Purpose: To assess the 12-month outcomes in subjects developing macular neovascularization (MNV) during intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Methods: This research was conducted as a case-controlled, retrospective study of AMD subjects undergoing IVA treatment for GA from two private practice institutions. Subjects were divided into 1) a Study Group of patients who developed MNV and then underwent anti-vascular endothelial growth factor (VEGF) therapy during the study period, and 2) a Control Group of patients who were complication-free during the study period.
BMJ Open
December 2024
Department of Psychiatry, University of Hong Kong, Hong Kong, China.
Introduction: Age-related macular degeneration (AMD) is a prevalent eye disease among middle-aged and older adults. AMD leaves the patient with irreversible deteriorating vision, which profoundly impacts their daily lives and psychosocial well-being. Given the limited studies addressing the psychosocial needs of adults with AMD and, in particular, using an expressive arts-based intervention (EXABI) as an intervention, this study aims to investigate the effectiveness of such an intervention in enhancing the psychosocial well-being of adults with AMD.
View Article and Find Full Text PDFEye (Lond)
January 2025
Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Objectives: The aim of the study was to evaluate anatomical and functional outcomes of the Smaller-Incision New Generation Implantable Miniature Telescope (SING IMT™) in patients with bilateral advanced age-related macular degeneration (AMD).
Methods: This non-comparative retrospective single-surgeon interventional case series included patients with bilateral late-stage AMD who underwent cataract surgery and SING IMT™ implantation at the Sant'Anna University Hospital, University of Ferrara, Italy. The main outcome measures included corrected distance (CDVA) and near visual acuity (CNVA), endothelial cell loss (ECL), and incidence of complications.
Eye (Lond)
January 2025
Bayer Consumer Care AG, Basel, Switzerland.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!